Literature DB >> 11567960

Is activated factor VII associated with retinal vein occlusion?

S Kadayifçilar1, D Ozatli, O Ozcebe, E C Sener.   

Abstract

AIM: To determine whether a newly identified thrombophilia factor, activated factor VII (FVIIa), is associated with retinal vein occlusion (RVO).
METHODS: 54 consecutive cases with RVO seen between March and September 1999 were included in the study. 22 cases had central retinal vein occlusion (CRVO) and 32 had branch retinal vein occlusion (BRVO). Ophthalmoscopic examination with detailed medical history was followed by blood analyses for liver and renal functions, cholesterol, triglycerides, complete blood count, and coagulation factors including protein C activity, free protein S, antithrombin III, fibrinogen, and factor VIIa (FVIIa). Data were compared with those of the control group, composed of 19 cases under ophthalmological follow up for refractive errors, presbyopia, or senile cataract.
RESULTS: Hypertension was highly prevalent in cases with BRVO. Complete blood count, and liver and kidney function tests were within normal limits in the study group. Two cases had low protein C activity, and one had low free protein S. FVIIa levels were significantly higher in the RVO group than in the control group (p=0.0004). There was no significant difference in FVIIa levels between the CRVO and BRVO groups (p=0.51).
CONCLUSION: No haematological parameter except FVIIa differed significantly from that of the control group. Elevation of FVIIa level may play a part in the pathophysiology of both CRVO and BRVO.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11567960      PMCID: PMC1723720          DOI: 10.1136/bjo.85.10.1174

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

Review 1.  Activation of the factor VII-tissue factor pathway.

Authors:  K A Bauer
Journal:  Thromb Haemost       Date:  1997-07       Impact factor: 5.249

2.  Activated protein C resistance in patients with central retinal vein occlusion.

Authors:  J Larsson; A Sellman; B Bauer
Journal:  Br J Ophthalmol       Date:  1997-10       Impact factor: 4.638

3.  Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

Authors:  J H Morrissey; B G Macik; P F Neuenschwander; P C Comp
Journal:  Blood       Date:  1993-02-01       Impact factor: 22.113

4.  Activated protein C resistance in young adults with central retinal vein occlusion.

Authors:  J Larsson; E Olafsdottir; B Bauer
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

5.  Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study.

Authors:  T H Williamson; A Rumley; G D Lowe
Journal:  Br J Ophthalmol       Date:  1996-03       Impact factor: 4.638

6.  Fluorogenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese.

Authors:  K Kario; T Miyata; T Sakata; T Matsuo; H Kato
Journal:  Arterioscler Thromb       Date:  1994-02

7.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.

Authors:  J Heinrich; L Balleisen; H Schulte; G Assmann; J van de Loo
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk.

Authors:  P L Lip; A D Blann; A F Jones; G Y Lip
Journal:  Eye (Lond)       Date:  1998       Impact factor: 3.775

9.  Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion.

Authors:  F Bandello; S Viganò D'Angelo; M Parlavecchia; A Tavola; P Della Valle; R Brancato; A D'Angelo
Journal:  Thromb Haemost       Date:  1994-07       Impact factor: 5.249

10.  Congenital protein C deficiency and myocardial infarction:concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis.

Authors:  K Kario; T Matsuo; S Tai; S Sakamoto; T Yamada; T Miki; M Matsuo
Journal:  Thromb Res       Date:  1992-07-01       Impact factor: 3.944

View more
  5 in total

1.  Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion.

Authors:  Marianne L Shahsuvaryan
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

2.  A longitudinal analysis of risk factors associated with central retinal vein occlusion.

Authors:  Maxwell S Stem; Nidhi Talwar; Grant M Comer; Joshua D Stein
Journal:  Ophthalmology       Date:  2012-11-20       Impact factor: 12.079

Review 3.  Impact of Retinal Vein Occlusion on Stroke Incidence: A Meta-Analysis.

Authors:  Min Li; Xiaolan Hu; Jiangtao Huang; Yuan Tan; Baoping Yang; Zhenyu Tang
Journal:  J Am Heart Assoc       Date:  2016-12-22       Impact factor: 5.501

4.  Comorbidity in patients with branch retinal vein occlusion: case-control study.

Authors:  Mette Bertelsen; Allan Linneberg; Thomas Rosenberg; Nynne Christoffersen; Henrik Vorum; Else Gade; Michael Larsen
Journal:  BMJ       Date:  2012-11-30

5.  Central retinal vein occlusion associated with platelet activation.

Authors:  Mehmet Citirik
Journal:  Ther Adv Ophthalmol       Date:  2019-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.